Wuhan Keqian Biology Co Ltd (SHG:688526) — Market Cap & Net Worth
Market Cap & Net Worth: Wuhan Keqian Biology Co Ltd (688526)
Wuhan Keqian Biology Co Ltd (SHG:688526) has a market capitalization of $999.26 Million (CN¥6.83 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #9160 globally and #2475 in its home market, demonstrating a -1.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Keqian Biology Co Ltd's stock price CN¥14.65 by its total outstanding shares 466128056 (466.13 Million). Analyse Wuhan Keqian Biology Co Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Wuhan Keqian Biology Co Ltd Market Cap History: 2020 to 2026
Wuhan Keqian Biology Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $2.71 Billion to $999.26 Million (-12.03% CAGR).
Wuhan Keqian Biology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Keqian Biology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.03x
Wuhan Keqian Biology Co Ltd's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.55x
Wuhan Keqian Biology Co Ltd's market cap is 2.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.71 Billion | $843.23 Million | $447.80 Million | 3.21x | 6.04x |
| 2021 | $1.80 Billion | $1.10 Billion | $570.74 Million | 1.64x | 3.16x |
| 2022 | $1.48 Billion | $1.00 Billion | $409.52 Million | 1.48x | 3.62x |
| 2023 | $1.36 Billion | $1.06 Billion | $395.93 Million | 1.28x | 3.43x |
| 2024 | $974.71 Million | $941.92 Million | $382.35 Million | 1.03x | 2.55x |
Competitor Companies of 688526 by Market Capitalization
Companies near Wuhan Keqian Biology Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Wuhan Keqian Biology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Wuhan Keqian Biology Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Wuhan Keqian Biology Co Ltd's market cap moved from $2.71 Billion to $ 999.26 Million, with a yearly change of -12.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥999.26 Million | -4.00% |
| 2025 | CN¥1.04 Billion | +6.79% |
| 2024 | CN¥974.71 Million | -28.29% |
| 2023 | CN¥1.36 Billion | -8.25% |
| 2022 | CN¥1.48 Billion | -17.92% |
| 2021 | CN¥1.80 Billion | -33.30% |
| 2020 | CN¥2.71 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Wuhan Keqian Biology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $999.26 Million USD |
| MoneyControl | $999.26 Million USD |
| MarketWatch | $999.26 Million USD |
| marketcap.company | $999.26 Million USD |
| Reuters | $999.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.